Original articles

Correlation of KIT and PDGFRA mutation status with clinicopathologic features in primary and recurrent or metastatic gastrointestinal stromal tumors

Expand
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2021-03-20

  Online published: 2022-06-28

Abstract

Objective: To investigate the correlation of KIT and PDGFRA mutation status with immunohistochemistry (IHC) and clinicopathological features in the primary, recurren tor metastatic gastrointestinal stromal tumors (GIST). Methods: A total of 167 primary GIST including 22 recurrent or metastatic GIST were tested for CD117, DOG1, CD34 and Ki-67 by IHC, and KIT gene exon 9, 11, 13, 17and PDGFRA gene exon12, 18 were analyzed by Sanger sequencing. Results: The frequencies of KIT and PDGFRA mutation in 167 primary GIST were 83.8%(140/167) and 3.0% (5/167), respectively. The mutation frequencies of KIT gene exon 11, exon 9 and exon 17 were 74.9% (125/167),8.4% (14/167) and 0.6% (1/167). Five primary GIST harbored PDGFRA mutations in exon 18,and 4 tumors had D842V mutation. Genetic mutations in KIT gene included point mutations (34.3%,48/140), deletion mutations (40.7%,57/140), duplication mutations (3.6%,5/140), and complicated mutations (deletion-insertion,12.1%,17/140).For GIST with KIT gene exon 11 mutation, Ki-67 index was significantly higher in tumors with non-point mutation than those with point mutations (P=0.0052). In 22 recurrent or metastatic GIST, double-exon mutation on KIT gene were found in 9 cases and 6 case were with mutation in both exon 11 and 17, 2 in exon 11 and 13,and one in exon 9 and 13.In 22 cases with recurrent or metastatic GIST, patients with double KIT exon mutations had a longer median progression-free survival (PFS)(108 months) than those with wild type gene (PFS, 30 months),and single exon mutation (PFS, 60 months)(P=0.0299 and P=0.0111), while no significant difference were observed regarding Ki-67, CD117, DOG1, CD34 expression,tumor size and nuclear mitosis between them. Conclusions: KIT mutations in primary GIST occur more often in exon 11. For primary GIST with KIT exon 11 mutations, Ki-67 index is higher in lesions with non-point mutation than those with point mutation,indicating poor biological beha-vior. In recurrence or metastatic GIST, cases harbor the double KIT exon mutations account for 9/22 and possess a better PFS than those with wild type and singe KIT exon 11 mutation.

Cite this article

GU Yijin, LI Anqi, DONG Lei, XU Haimin, SHEN Xia, XIE Jialing, YUAN Fei, WANG Chaofu . Correlation of KIT and PDGFRA mutation status with clinicopathologic features in primary and recurrent or metastatic gastrointestinal stromal tumors[J]. Journal of Diagnostics Concepts & Practice, 2021 , 20(03) : 257 -264 . DOI: 10.16150/j.1671-2870.2021.03.006

References

[1] Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour[J]. Lancet, 2013, 382(9896):973-983.
[2] Corless CL. Gastrointestinal stromal tumors: what do we know now?[J]. Mod Pathol, 2014, 27(Suppl 1):S1-S16.
[3] 徐佳, 赵文毅, 庄淳, 等. 胃肠道间质瘤术后伊马替尼辅助治疗停药后复发的危险因素分析[J]. 中国普通外科杂志, 2016, 31(2):104-107.
[4] Shen YY, Ma XL, Wang M, et al. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors[J]. Cancer Med, 2020, 9(18):6485-6496.
[5] Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002, 347(7):472-480.
[6] Nishida T, Blay JY, Hirota S, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines[J]. Gastric Cancer, 2016, 19(1):3-14.
[7] Debiec-Rychter M. Sunitinib--a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor[J]. Nat Clin Pract Oncol, 2007, 4(6):342-343.
[8] Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship[J]. Clin Cancer Res, 2003, 9(1):327-337.
[9] Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9863):295-302.
[10] George S, Jones RL, Bauer S, et al. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy[J]. Oncologist, 2021, 26(4):e639-e649.
[11] Falkenhorst J, Hamacher R, Bauer S. New therapeutic agents in gastrointestinal stromal tumours[J]. Curr Opin Oncol, 2019, 31(4):322-328.
[12] Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy[J]. Annu Rev Med, 2012, 63:247-258.
[13] 中国胃肠道间质瘤病理共识意见专家组. 中国胃肠道间质瘤诊断治疗专家共识(2017年版)病理解读[J]. 中华病理学杂志, 2018, 47(1):2-6.
[14] 许海敏, 陈晓炎, 董磊, 等. 不同克隆号 ALK 抗体在炎性肌纤维母细胞肿瘤中的表达比较研究[J]. 诊断病理学杂志, 2020, 27(9):629-632,636.
[15] Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors[J]. J Clin Oncol, 2005, 23(1):49-57.
[16] Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor[J]. Hum Pathol, 2008, 39(10):1411-1419.
[17] Nannini M, Tarantino G, Indio V, et al. Molecular mode-lling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient respon-ding to imatinib[J]. Sci Rep, 2019, 9(1):2172.
[18] Wang M, Xu J, Zhao W, et al. Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases[J]. Med Oncol, 2014, 31(1):819.
[19] Wozniak A, Rutkowski P, Schöffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST[J]. Clin Cancer Res, 2014, 20(23):6105-6116.
[20] Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study[J]. Ann Oncol, 2010, 21(7):1552-1557.
[21] 中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版)[J]. 肿瘤综合治疗电子杂志, 2018, 4(1):31-43.
[22] Artigiani Neto R, Logullo AF, Stávale JN, et al. Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors(GIST)[J]. Acta Cir Bras, 2012, 27(5):315-321.
[23] 朱从波, 廖国庆, 赵丁民. Ki-67对胃肠道间质瘤预后的评估价值[J]. 临床与病理杂志, 2018, 38(8):1632-1639.
[24] Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of Phase 3 SWOG Intergroup Trial S0033[J]. JAMA Oncol, 2017, 3(7):944-952.
[25] Vanden Bempt I, Vander Borght S, Sciot R, et al. Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor[J]. Genes Chromosomes Cancer, 2021, 60(4):239-249.
[26] 孟琳, 张声. KIT基因双突变在胃肠道间质瘤中的作用[J]. 临床与病理杂志, 2018, 38(4): 830-836.
[27] Bosbach B, Deshpande S, Rossi F, et al. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor[J]. Proc Natl Acad Sci U S A, 2012, 109(34):E2276-E2283.
[28] Kang DY, Park CK, Choi JS, et al. Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients[J]. Am J Surg Pathol, 2007, 31(2):224-232.
[29] Xu C, Liu YL, Yu HY, et al. Synchronous and metachronous multiple gastrointestinal stromal tumors[J]. Histol Histopathol, 2012, 27(2):225-234.
Outlines

/